Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during ...
Barchart on MSN
Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.
Kenvue (KVUE) could really use some good news. The Johnson & Johnson (JNJ) spinoff faced longlasting troubles regarding its ...
Perimenopausal women who used estrogen for at least 10 years before their periods stopped had 60% lower odds for breast ...
Kenvue, the maker of Tylenol, is urging U.S. health regulators not to add an autism warning label to it and other ...
The maker of Tylenol is urging U.S. health regulators not to add an autism warning label to it and other pain-relievers ...
Johnson & Johnson stopped selling its talc-based baby powder in the US and Canada in 2020. In 2023, it switched to a cornstarch formula. The company maintains its baby powder is safe. Its consumer ...
Kenvue, the maker of Tylenol, opposes proposed changes to the product's safety label regarding potential links to autism and ...
The U.S. Food and Drug Administration (FDA) has classified the recall of Neutrogena Makeup Remover Ultra-Soft Cleansing ...
Tylenol maker Kenvue is calling on the Food and Drug Administration (FDA) to back off a proposed safety label change to ...
Kenvue, the owners of Tylenol, are pushing back on claims that acetaminophen—the chemical compound in their popular ...
Kenvue Inc's (NYSE: KVUE) short interest as a percent of float has fallen 20.2% since its last report. According to exchange reported data, there are now 34.24 million shares sold short, which is 2.37 ...
Kenvue stock drops 30% YTD, but Starboard's Jeff Smith remains optimistic, citing leadership changes and brand improvements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback